Protaryx Medical announced today that it raised $8.3 million for the development of its first-in-class device for transseptal access to the left atrium.
The Baltimore-based company’s funding includes non-dilutive grants and a seed round totaling $3.2 million, along with a recently closed $5.1 million Series A round led by Ajax Health, with participation from returning investor University of Maryland Ventures.
Protaryx’s device is designed for use in catheter-based procedures, including mitral valve repair and replacement, left atrial appendage closure and catheter ablation to treat cardiac arrhythmias, according to a news release.
The company designed the system to give physicians confidence in accuracy and safety during procedures through independent steerability and three-dimensional control, streamlining rapid crossing to the left heart. Currently, the Protaryx device is not commercially available anywhere.
“There is currently an op…